Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline bioequivalence study in healthy Chinese subjects
NCT07008417Phase 1Active, not recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cabergoline in hyperprolactinemia (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve from 0 to 72 hours. Started Jun 2025; status: active, not recruiting.
02
Drugs
cabergoline
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on NCT07008417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008417.